Sevelamer Carbonate Tablet, Film Coated
Product Images NDC 55154-3358

4 FDA label images from Cardinal Health 107, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 55154-3358). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C9310ad4 3c5e 4937 8cc8 6614db32a675 00

C9310ad4 3c5e 4937 8cc8 6614db32a675 00
Label for Sevelamer Carbonate tablets 800 mg, film-coated oral tablets. The label includes product name, strength, quantity of 10 tablets, active ingredient content, storage instructions at 20°-25°C, and distribution details. It notes the product is prescription only and intended for institutional use, not child-resistant. Manufacturer is Dr Reddy's Laboratories Limited, India, with distribution by Major Pharmaceuticals and Cardinal Health.*
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
Chemical structure diagram of the active ingredient Sevelamer Carbonate, showing its polymeric amine groups and carbonate counter ions. The structure includes repeating units with amine (NH3+, NH2) and hydroxyl (OH) functionalities linked in a polymeric chain.*
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
A line graph comparing the percentage of patients with at least 2 times reduction in serum phosphorus levels versus the reduction from baseline in serum phosphorus (mg/dL) for Sevelamer Hydrochloride and an Active Control. The graph shows trends of improvement and worsening in serum phosphorus levels among patients.*
FDA Label Image

Figure3 (Figure3)

Figure3 (Figure3)
A line chart depicting phosphorus change from baseline over a 52-week study period. The x-axis marks study weeks from 0 to 52; the y-axis shows phosphorus change ranging from -5 to 2. Two lines represent treatment groups: Sevelamer Hydrochloride and an active control, illustrating trends in phosphorus levels throughout the study.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.